Comprehensive Stock Comparison
Compare Stoke Therapeutics, Inc. (STOK) vs CRISPR Therapeutics AG (CRSP) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | STOK | 316.3% revenue growth vs CRSP's -90.0% |
| Quality / Margins | STOK | 19.7% net margin vs CRSP's -13.3% |
| Stability / Safety | STOK | Beta 0.80 vs CRSP's 1.25, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | STOK | +363.8% vs CRSP's +36.9% |
| Efficiency (ROA) | STOK | 11.3% ROA vs CRSP's -21.7%, ROIC -206.8% vs -27.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Stoke Therapeutics is an early-stage biopharmaceutical company developing antisense oligonucleotide medicines that target the root causes of severe genetic diseases. It generates revenue primarily through research collaborations and licensing agreements — like its partnership with Acadia Pharmaceuticals — while advancing its own pipeline, including lead candidate STK-001 for Dravet syndrome. The company's key advantage is its proprietary TANGO platform, which enables precise upregulation of protein expression to address genetic deficiencies that traditional therapies cannot.
CRISPR Therapeutics is a clinical-stage biotechnology company developing transformative gene-editing therapies for serious diseases using its proprietary CRISPR/Cas9 platform. It generates revenue primarily through research collaborations and milestone payments from partners like Vertex Pharmaceuticals — with its lead therapy for sickle cell disease and beta-thalassemia now approved and generating product sales. The company's key advantage is its foundational CRISPR/Cas9 intellectual property and extensive expertise in developing ex vivo gene-edited cell therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
STOK leads in 5 of 6 categories — strongest in Financial Metrics and Valuation Metrics.
Financial Metrics (TTM)
STOK is the larger business by revenue, generating $206M annually — 5.6x CRSP's $37M. STOK is the more profitable business, keeping 19.7% of every revenue dollar as net income compared to CRSP's -13.3%.
| Metric | STOKStoke Therapeutic… | CRSPCRISPR Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $206M | $37M |
| EBITDAEarnings before interest/tax | $30M | -$556M |
| Net IncomeAfter-tax profit | $41M | -$488M |
| Free Cash FlowCash after capex | $52M | -$303M |
| Gross MarginGross profit ÷ Revenue | +99.5% | -3.6% |
| Operating MarginEBIT ÷ Revenue | +13.2% | -15.6% |
| Net MarginNet income ÷ Revenue | +19.7% | -13.3% |
| FCF MarginFCF ÷ Revenue | +25.5% | -8.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +117.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -38.3% | -15.8% |
Valuation Metrics
| Metric | STOKStoke Therapeutic… | CRSPCRISPR Therapeuti… |
|---|---|---|
| Market CapShares × price | $2.0B | $5.6B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $5.5B |
| Trailing P/EPrice ÷ TTM EPS | -22.07x | -9.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 54.90x | 1608.41x |
| Price / BookPrice ÷ Book value/share | 8.59x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
STOK delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-25 for CRSP. STOK carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRSP's 0.11x. On the Piotroski fundamental quality scale (0–9), STOK scores 4/9 vs CRSP's 2/9, reflecting mixed financial health.
| Metric | STOKStoke Therapeutic… | CRSPCRISPR Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | +13.2% | -25.5% |
| ROA (TTM)Return on assets | +11.3% | -21.7% |
| ROICReturn on invested capital | -2.1% | -27.4% |
| ROCEReturn on capital employed | -47.3% | -31.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.11x |
| Net DebtTotal debt minus cash | -$126M | -$141M |
| Cash & Equiv.Liquid assets | $128M | $348M |
| Total DebtShort + long-term debt | $2M | $207M |
| Interest CoverageEBIT ÷ Interest expense | 10221.67x | — |
Total Returns (with DRIP)
A $10,000 investment in STOK five years ago would be worth $5,955 today (with dividends reinvested), compared to $4,617 for CRSP. Over the past 12 months, STOK leads with a +363.8% total return vs CRSP's +36.9%. The 3-year compound annual growth rate (CAGR) favors STOK at 60.0% vs CRSP's 6.8% — a key indicator of consistent wealth creation.
| Metric | STOKStoke Therapeutic… | CRSPCRISPR Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +17.8% | +11.8% |
| 1-Year ReturnPast 12 months | +363.8% | +36.9% |
| 3-Year ReturnCumulative with dividends | +309.6% | +21.9% |
| 5-Year ReturnCumulative with dividends | -40.4% | -53.8% |
| 10-Year ReturnCumulative with dividends | +42.4% | +326.8% |
| CAGR (3Y)Annualised 3-year return | +60.0% | +6.8% |
Risk & Volatility
STOK is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than CRSP's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. STOK currently trades 94.1% from its 52-week high vs CRSP's 76.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | STOKStoke Therapeutic… | CRSPCRISPR Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.80x | 1.25x |
| 52-Week HighHighest price in past year | $38.69 | $78.48 |
| 52-Week LowLowest price in past year | $5.35 | $30.04 |
| % of 52W HighCurrent price vs 52-week peak | +94.1% | +76.6% |
| RSI (14)Momentum oscillator 0–100 | 62.8 | 66.2 |
| Avg Volume (50D)Average daily shares traded | 560K | 1.4M |
Analyst Outlook
Wall Street rates STOK as "Buy" and CRSP as "Buy". Consensus price targets imply 17.4% upside for STOK (target: $43) vs 8.1% for CRSP (target: $65).
| Metric | STOKStoke Therapeutic… | CRSPCRISPR Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $42.75 | $65.00 |
| # AnalystsCovering analysts | 15 | 38 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Stoke Therapeutics,… (STOK) | 100 | 114.34 | +14.3% |
| CRISPR Therapeutics… (CRSP) | 100 | 96.18 | -3.8% |
Stoke Therapeutics,… (STOK) returned -40% over 5 years vs CRISPR Therapeutics… (CRSP)'s -54%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Stoke Therapeutics,… (STOK) | $0.00 | $37M | — |
| CRISPR Therapeutics… (CRSP) | $5M | $4M | -32.0% |
CRISPR Therapeutics AG's revenue grew from $5M (2016) to $4M (2025) — a -4.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Stoke Therapeutics,… (STOK) | -8.1% | -2.4% | +70.1% |
| CRISPR Therapeutics… (CRSP) | -4.5% | -165.7% | -3587.9% |
CRISPR Therapeutics AG's net margin went from -4% (2016) to -166% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Stoke Therapeutics,… (STOK) | -0.24 | -1.65 | -587.5% |
| CRISPR Therapeutics… (CRSP) | -1.89 | -6.47 | -242.3% |
CRISPR Therapeutics AG's EPS grew from $-1.89 (2016) to $-6.47 (2025).
Chart 5Free Cash Flow — 5 Years
Stoke Therapeutics, Inc. generated $-87M FCF in 2024 (-28% vs 2021). CRISPR Therapeutics AG generated $-346M FCF in 2025 (-176% vs 2021).
STOK vs CRSP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is STOK or CRSP a better buy right now?
Analysts rate Stoke Therapeutics, Inc. (STOK) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — STOK or CRSP?
Over the past 5 years, Stoke Therapeutics, Inc. (STOK) delivered a total return of -40.4%, compared to -53.8% for CRISPR Therapeutics AG (CRSP). A $10,000 investment in STOK five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CRSP returned +326.8% versus STOK's +42.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — STOK or CRSP?
By beta (market sensitivity over 5 years), Stoke Therapeutics, Inc. (STOK) is the lower-risk stock at 0.80β versus CRISPR Therapeutics AG's 1.25β — meaning CRSP is approximately 56% more volatile than STOK relative to the S&P 500. On balance sheet safety, Stoke Therapeutics, Inc. (STOK) carries a lower debt/equity ratio of 1% versus 11% for CRISPR Therapeutics AG — giving it more financial flexibility in a downturn.
04Which has better profit margins — STOK or CRSP?
Stoke Therapeutics, Inc. (STOK) is the more profitable company, earning -243.4% net margin versus -165.7% for CRISPR Therapeutics AG — meaning it keeps -243.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STOK leads at -277.3% versus -189.3% for CRSP. At the gross margin level — before operating expenses — STOK leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — STOK or CRSP?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is STOK or CRSP better for a retirement portfolio?
For long-horizon retirement investors, Stoke Therapeutics, Inc. (STOK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.80)). Both have compounded well over 10 years (STOK: +42.4%, CRSP: +326.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between STOK and CRSP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.